BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 9419966)

  • 21. Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study.
    Cesario A; Catassi A; Festi L; Imperatori A; Pericelli A; Galetta D; Margaritora S; Porziella V; Cardaci V; Granone P; Dominioni L; Russo P
    Clin Cancer Res; 2005 Mar; 11(5):2026-37. PubMed ID: 15756029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model.
    Shannon P; Sabha N; Lau N; Kamnasaran D; Gutmann DH; Guha A
    Am J Pathol; 2005 Sep; 167(3):859-67. PubMed ID: 16127163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor-receptor mutant lacking the autophosphorylation sites induces phosphorylation of Shc protein and Shc-Grb2/ASH association and retains mitogenic activity.
    Gotoh N; Tojo A; Muroya K; Hashimoto Y; Hattori S; Nakamura S; Takenawa T; Yazaki Y; Shibuya M
    Proc Natl Acad Sci U S A; 1994 Jan; 91(1):167-71. PubMed ID: 7506413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma.
    Janzarik WG; Kratz CP; Loges NT; Olbrich H; Klein C; Schäfer T; Scheurlen W; Roggendorf W; Weiller C; Niemeyer C; Korinthenberg R; Pfister S; Omran H
    Neuropediatrics; 2007 Apr; 38(2):61-3. PubMed ID: 17712732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on ras in human hepatic stellate cells.
    Carloni V; Pinzani M; Giusti S; Romanelli RG; Parola M; Bellomo G; Failli P; Hamilton AD; Sebti SM; Laffi G; Gentilini P
    Hepatology; 2000 Jan; 31(1):131-40. PubMed ID: 10613738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Shc adaptor proteins are key transducers of mitogenic signaling mediated by the G protein-coupled thrombin receptor.
    Chen Y; Grall D; Salcini AE; Pelicci PG; Pouysségur J; Van Obberghen-Schilling E
    EMBO J; 1996 Mar; 15(5):1037-44. PubMed ID: 8605873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
    Crul M; de Klerk GJ; Beijnen JH; Schellens JH
    Anticancer Drugs; 2001 Mar; 12(3):163-84. PubMed ID: 11290863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targets of p56(lck) activity in immature thymoblasts: stimulation of the Ras/Raf/MAPK pathway.
    Lin K; Abraham KM
    Int Immunol; 1997 Feb; 9(2):291-306. PubMed ID: 9040011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
    Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.
    Lau N; Feldkamp MM; Roncari L; Loehr AH; Shannon P; Gutmann DH; Guha A
    J Neuropathol Exp Neurol; 2000 Sep; 59(9):759-67. PubMed ID: 11005256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contribution of Src and Ras pathways in FGF-2 induced endothelial cell differentiation.
    Klint P; Kanda S; Kloog Y; Claesson-Welsh L
    Oncogene; 1999 Jun; 18(22):3354-64. PubMed ID: 10362356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1.
    Farassati F; Yang AD; Lee PW
    Nat Cell Biol; 2001 Aug; 3(8):745-50. PubMed ID: 11483960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Farnesyltransferase inhibitor FTI-277 prevents autocrine growth stimulation of neuroblastoma by BDNF.
    Girgert R; Wittrock J; Pfister S; Schweizer P
    J Cancer Res Clin Oncol; 2003 Apr; 129(4):227-33. PubMed ID: 12700894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells.
    Watanabe M; Nobuta A; Tanaka J; Asaka M
    Int J Cancer; 1996 Jul; 67(2):264-8. PubMed ID: 8760597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased mitogenic response to epidermal growth factor in human squamous cell carcinoma lines overexpressing epidermal growth factor receptor owing to limiting amounts of the adaptor protein Grb2: rescue by retinoic acid treatment.
    Crowe DL; Tsang KJ
    Mol Carcinog; 2001 Dec; 32(4):187-94. PubMed ID: 11746830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ras activation in response to phorbol ester proceeds independently of the EGFR via an unconventional nucleotide-exchange factor system in COS-7 cells.
    Rubio I; Rennert K; Wittig U; Beer K; Dürst M; Stang SL; Stone J; Wetzker R
    Biochem J; 2006 Sep; 398(2):243-56. PubMed ID: 16709153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
    Nammi S; Lodagala DS
    Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases.
    Rozakis-Adcock M; McGlade J; Mbamalu G; Pelicci G; Daly R; Li W; Batzer A; Thomas S; Brugge J; Pelicci PG; Schlessinger J; Pawson T
    Nature; 1992 Dec; 360(6405):689-92. PubMed ID: 1465135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways.
    Gu J; Tamura M; Yamada KM
    J Cell Biol; 1998 Nov; 143(5):1375-83. PubMed ID: 9832564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.